Teva Pharma (TEVA) Sinks 16% on Weak Results, Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Credit Suisse Downgrades Teva Pharma (TEVA) to Neutral
August 4, 2017 6:01 AM EDTCredit Suisse downgraded Teva Pharma (NYSE: TEVA) from Outperform to Neutral with a price target of $25.00 (from $39.00).
Analyst Vamil Divan said as they look ahead they believe there are still no signs of stabilization for some of the key issues impacting TEVAs core... More
RBC Capital Double Downgrades Teva Pharma (TEVA) to Underperform
August 4, 2017 5:54 AM EDTRBC Capital downgraded Teva Pharma (NYSE: TEVA) from Outperform to Underperform with a price target of $21.00 (from $37.00).
Analyst Randall Stanicky comments "the magnitude of the reduction and low quality results combined with leverage risk and lack of confidence in TEVA's ability to... More
Cowen Downgrades Teva Pharma (TEVA) to Market Perform
August 4, 2017 5:51 AM EDTCowen downgraded Teva Pharma (NYSE: TEVA) from Outperform to Market Perform with a price target of $30.00 (from $50.00).
Analyst Ken Cacciatore says the valuation is bottoming but sees better options for long investments elsewhere.
For an analyst ratings summary and ratings... More
Teva Pharma (TEVA) Cracks Fresh Low, Now Down 19.65%
August 3, 2017 11:17 AM EDTTeva Pharma (NYSE: TEVA) Cracks Fresh Low, Now Down 19.65%
... MoreMylan (MYL) Sinks Following Teva Results, Outlook
August 3, 2017 8:13 AM EDTMylan (NASDAQ: MYL) trades down 3.9% following weak results and outlook from rival Teva. Teva is down 15%.
... MoreTeva Pharma (TEVA) Lowers Quarterly Dividend 75% to $0.085; 1.1% Yield
August 3, 2017 6:35 AM EDTTeva Pharma (NYSE: TEVA) declared a quarterly dividend of $0.085 per share, or $0.34 annualized. This is a 75% decrease from the prior dividend of $0.34.
The dividend will be payable on September 14, 2017, to stockholders of record on August 29, 2017, with an ex-dividend date of August 25,... More
Teva Pharma (TEVA) Misses Q2 EPS by 4c, Lowers FY EPS Guidance, Cuts Dividend
August 3, 2017 6:33 AM EDT(Updated - August 3, 2017 6:40 AM EDT)
Teva Pharma (NYSE: TEVA) reported Q2 EPS of $1.02, $0.04 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.76 billion.
GUIDANCE:
Teva Pharma sees Q3 2017 EPS of $4.30-$4.50, versus the consensus of $4.74.
We... More